
NB : INOVIS Inc. is the boutique branch of the global INOVIS group that specializes in creative, tailored, proactive CI services for a select number of InfoTech & MedTech clients. By comparison, INOVIS AG, which focusses on Pharma & Biotech, is a mid-sized agency offering both bespoke CI solutions and proprietary in-house CI tools to a broader client base in the Life Sciences field. Both the Pharma and Tech sides' strict specialty and focus create synergies from each entity's talent pool and experience.

Without direct observation and engagement regarding your market, competitors, customers, or operating environment, you’re essentially planning in the dark. You might overlook emerging market trends, changing customer preferences, foreign market peculiarities, or competitors' vulnerabilities because you aren't gathering vital intelligence directly from the source. Your strategic plan may end up targeting the wrong opportunities or, worse, leave you vulnerable to actual threats. [LINK to Entry Bungles]
Every strategy relies on assumptions about the future, customer behavior, market dynamics, and your own capabilities. Primary intelligence allows you to test and validate these assumptions before fully committing to a course of action. Without it, you risk constructing your entire strategic approach on an unverified foundation. Slower Learning and Adaptation: Markets are constantly evolving. Primary intelligence facilitates feedback loops that enable you to adjust your strategy as conditions change. Without these direct information channels, you may be slow to recognize when your strategy needs recalibration and may miss critical opportunities to act proactively. [LINK 6] This doesn't mean AI data and analysis aren't valuable— absolutely, they are! AI helps unearth patterns and guide inquiry, while primary research fills in gaps, validates assumptions, and uncovers information that wouldn’t be evident through data alone. AI provides speed and scale for analyzing secondary data, detecting trends, and identifying signals, but primary intelligence provides the context, nuance, and deeper understanding of "why" things are happening. The most effective strategic planning combines primary intelligence with secondary sources to create a comprehensive, reality-tested view of your strategic landscape. INOVIS has been doing precisely that for over 3 decades. Interested in our process? Let’s Chat!
Being present in the field—whether that’s maintaining an ongoing connection with industry experts, attending industry events, or monitoring online communities— and listening actively gives you a feel for momentum, sentiment, and emerging patterns before they show up in quarterly data.
This doesn't mean AI data and analysis aren't valuable— absolutely, they are! But they're most powerful when combined with that visceral, firsthand, human understanding.
For over three decades, INOVIS’ competitive intelligence techniques have been massively successful at sufacing a firsthand, in-depth understanding of markets, competitors, and customers.

Since 1992, INOVIS has supported decision-making, implementation and execution across the LIFE SCIENCES and TECHNOLOGIES sectors, leveraging world-class CI and marketing expertise through a network of experienced senior industry leaders who advance strategic thinking and nurture company and brand strategies.
If you think our specialized services might be a great match for your competitive strategy development,
OR, if you are interested in working with a tight-knit, dynamic team [ more info ] ,

A 30+year veteran in the CI and counter-intelligence industry, Marc Limacher has grown INOVIS into a global leader in primary intelligence and strategic consulting services, serving a select group of global Fortune 100 companies as loyal clients. He is responsible for the overall strategic direction of the firm and manages the operation of the Technologies practice.
Prior to INOVIS, Marc was Director of Market Intelligence at a leading U.S. institutional investment firm for five years, providing primary intelligence on small-/medium-/large-cap life science equities via a global employee network of 125 investigative journalists. He also delivers private CI seminars and is a frequent lecturer on CI and counter-intelligence topics at companies and to academia.
